ライフサイエンスコーパス: life expectancy

1 OR, 0.4; 95% CI, 0.3 to 0.6 for </= 10-year life expectancy).

2 baseline modified Rankin Scale [mRS] score, life expectancy).

3 Telomere length at birth has been related to life expectancy.

4 sions have significant dyspnea and shortened life expectancy.

5 edicted to depend on broader factors shaping life expectancy.

6 and atrophy, paralysis, and have diminished life expectancy.

7 onoscopy), reach age 75 or have <10 years of life expectancy.

8 ased because of organ shortage and increased life expectancy.

9 e prescribed only to those with a reasonable life expectancy.

10 conjugate bilirubin and may present a normal life expectancy.

11 tion depends on external factors influencing life expectancy.

12 it greater morbidity than men despite higher life expectancy.

13 ce between waitlist and post-transplantation life expectancy.

14 s, that compromise quality of life and limit life expectancy.

15 tality over the past century have focused on life expectancy.

16 llingness-to-pay or as income from increased life expectancy.

17 luate factors associated with differences in life expectancy.

18 tional-hazards models were used to calculate life expectancy.

19 o have significant comorbidities and limited life expectancy.

20 ce between post-transplantation and waitlist life expectancy.

21 century have seen a sharp increase in human life expectancy.

22 lasms (MPNs) are associated with a shortened life expectancy.

23 or CLT, and followed up over their remaining life expectancy.

24 to widening health inequalities and reduced life expectancy.

25 o a perceived limited control and to a short life expectancy.

26 ncidence, mean age at diagnosis, and average life expectancy.

27 ce of illness, lives saved, and increases in life expectancy.

28 sion of healthy life expectancy, and overall life expectancy.

29 in skin of mammalian species with different life expectancies.

30 monthly transition probabilities and 5-year life expectancies.

31 The outcomes of the model included life expectancy, 1-year and 5-year patient survival, and

32 y was valued more highly than posttransplant life expectancy; 1 year less of pretransplant life expec

33 Individualized control decreased life expectancy (20.63 vs. 20.73 years) due to an increa

34 The birth and 6 weeks strategy maximized life expectancy (26.5 years in the HIV-infected group an

35 ; and factors associated with differences in life expectancy across areas.

36 ificant difference in unadjusted or adjusted life expectancy across hospital risk-standardized mortal

37 d with greater longevity, and differences in life expectancy across income groups increased over time

38 The female life expectancy advantage over men is likely to shrink b

39 between longer D2B and D2N times and shorter life expectancy after AMI.

40 zip code-level median household income), and life expectancy after AMI.

41 Identifying patients with a limited life expectancy after TEVAR is possible using a preopera

42 der, and have more comorbidities and shorter life expectancy, all of which may limit the benefit of I

43 Cost parameters for a prototypical patient's life expectancy also were modeled and calculated.

44 te disease progression, quality of life, and life expectancy among individuals with HCV infection and

45 Within each case-mix stratum, we compared life expectancy among patients admitted to high-performi

46 s admitted to high-performing hospitals with life expectancy among patients admitted to low-performin

47 tal heart disease (CHD), allowing for longer life expectancies and an increasing number who will requ

48 ween prefectures with the lowest and highest life expectancies and HALE have widened, from 2.5 to 3.1

49 years have seen substantial improvements in life expectancy and access to antimicrobials, especially

50 evalent today because of recent increases in life expectancy and body mass index (BMI), but this assu

51 In this analysis, we estimated life expectancy and cause-specific mortality within King

52 ETATION: This census tract-level analysis of life expectancy and cause-specific YLL rates highlights

53 achines with controllable function, specific life expectancy and greater consistency.

54 ty in adolescence is associated with reduced life expectancy and impaired quality of life.

55 With the increase in life expectancy and improved access to health care, more

56 However, the association between life expectancy and income varied substantially across a

57 We noted a correlation between increased life expectancy and increased surgical rates up to 1533

58 benefits, and results in meaningful gains in life expectancy and large numbers of years of life saved

59 wo straight lines describe the joint rise of life expectancy and lifespan equality: one for primates

60 The life expectancy and loss in expectation of life were pre

61 However, little is known about how life expectancy and mortality from different causes of d

62 atio, 0.4; 95% CI, 0.3 to 0.8 for </= 5-year life expectancy and OR, 0.4; 95% CI, 0.3 to 0.6 for </=

63 region has historically seen improvements in life expectancy and other health indicators, even under

64 Life expectancy and quality of life for those born with

65 hemical treatment, especially to improve the life expectancy and quality of life of patients with pro

66 Measurements: Lifetime breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs),

67 ability, and mortality to forecast trends in life expectancy and the burden of disability in England

68 Reliable estimation of future trends in life expectancy and the burden of disability is crucial

69 The true effect of Barrett's oesophagus on life expectancy and the efficacy of long-term surveillan

70 ife history parameters like generation time, life expectancy and the variance in lifetime reproductiv

71 e culminating in a significantly compromised life expectancy and transformation to aggressive disease

72 escribe population-level trends in the adult life expectancy and trends in the residual burden of HIV

73 consistent relationships between changes in life expectancy and variance either within countries ove

74 all-cause mortality varied and gaps between life expectancy and years lived in full health, as measu

75 Life expectancy and years of life saved after AMI were c

76 in, and time to fibrinolysis </=30 min) with life expectancy and years of life saved after AMI.

77 ageing PLHIV are crucial to address shorter life expectancies, and improve their healthy states.

78 substantial morbidity, costs, and decreased life expectancy, and continues to rise worldwide.

79 Ds), disability-adjusted life-years (DALYs), life expectancy, and healthy life expectancy (HALE) in J

80 ancy is predicted to increase more than male life expectancy, and in Chile, France, and Greece where

81 lute differences in life expectancy, healthy life expectancy, and life expectancy with disability acc

82 to project life expectancy, quality-adjusted life expectancy, and lifetime medical costs in order to

83 ncy with disability, an extension of healthy life expectancy, and overall life expectancy.

84 ctors, medications used to reach the target, life expectancy, and patient preferences about treatment

85 proportion of all people with the disorder, life expectancy, and residential status.

86 iring treatment and the potential to shorten life expectancy are greater for CLL.

87 Whether rises in life expectancy are increases in good-quality years is o

88 Projections of future mortality and life expectancy are needed to plan for health and social

89 n older breast cancer survivors with limited life expectancy are not known, and there are important r

90 Interventions that aim to improve life expectancy are often prioritised without rigorous a

91 Aging population and longer life expectancy are the main reasons for an increasing n

92 ions in the dystrophin gene, with an average life expectancy around 25 years of age.

93 of mSqCLC, to evaluate the costs and patient life expectancies associated with each regimen.

94 sed to estimate race- and ethnicity-adjusted life expectancy at 40 years of age by household income p

95 ods to estimate gains in the population-wide life expectancy at age 15 years since the introduction o

96 Between 1991 and 2011, gains in life expectancy at age 65 years (4.5 years for men and 3

97 Disability-free life expectancy at age 65 years will increase by 1.0 yea

98 further in the next decade, but a quarter of life expectancy at age 65 years will involve disability.

99 ted that sacubitril/valsartan would increase life expectancy at an ICER consistent with other high-va

100 There is a greater than 95% probability that life expectancy at birth among men in South Korea, Austr

101 There is a 90% probability that life expectancy at birth among South Korean women in 203

102 e used age-specific death rates to calculate life expectancy at birth and at age 65 years, and probab

103 significant heterogeneity among provinces in life expectancy at birth and probability of death at age

104 ina have made substantial strides to improve life expectancy at birth between 1990 and 2013.

105 rer outcomes for Indigenous populations for: life expectancy at birth for 16 of 18 populations with a

106 Life expectancy at birth in Japan increased by 4.2 years

107 More than half of the projected gains in life expectancy at birth in women will be due to enhance

108 to age 5 years and from age 15 to 60 years, life expectancy at birth, and cause-specific and age-spe

109 experience an approximately 1-y increase in life expectancy at birth, and that there would be a cumu

110 the numbers of deaths and in life years and life expectancy at birth, attributable to changes in PM2

111 on mortality in adults (age >/=30y), and on life expectancy at birth, in the contiguous United State

112 Data were obtained for population, life expectancy at birth, infant mortality, low and high

113 oecomonic status gradients for mortality and life expectancy at birth, with outcomes improving with i

114 ectancy if MELD was </=27 but could decrease life expectancy at higher MELD scores.

115 In particular, some advocate forecasts of life expectancy based on period trends; others favor for

116 Changes in life expectancy between 2001 and 2014 ranged from gains

117 igh and is a primary cause of disparities in life expectancy between African Americans and whites.

118 was associated with a 2.1-year reduction in life expectancy between ages 40 and 85 years, the corres

119 roup; there was no significant difference in life expectancy between the groups (both 4.2 yrs; P = 0.

120 The gap in life expectancy between the richest 1% and poorest 1% of

121 t mice that reached adulthood showed reduced life expectancy, brain malformations including hippocamp

122 Here we examine the life expectancy, breakdown, and device failure of engine

123 y been found to be associated with decreased life expectancy, but little is known about whether this

124 f age-related chronic conditions and reduced life-expectancy, but the underlying biomolecular mechani

125 97 million lives and significantly increase life expectancy by 3.1-8.4 years, depending on the count

126 traumatic brain injury (TBI) shortened mean life expectancy by 8.7 years and by as much as 13 years

127 arch, 2011, the Syrian civil war has lowered life expectancy by as much as 20 years.

128 etween income and life expectancy; trends in life expectancy by income group; geographic variation in

129 apamycin treatment is sufficient to increase life expectancy by up to 60% and improve measures of hea

130 prevalence and disabled and disability-free life expectancy by year.

131 egistration data for King County to estimate life expectancy, cause-specific mortality rates, and yea

132 althy state was defined as the proportion of life expectancy comorbid-free, and was adjusted on the p

133 d the shortfall of the population-wide adult life expectancy compared with that of the HIV-negative p

134 Men have a shorter life expectancy compared with women but the underlying f

135 utting Mexico back on a track of substantial life expectancy convergence with better performing count

136 Effectiveness was measured via mortality and life-expectancy data.

137 Estimated life expectancy declined as hospital risk-standardized m

138 dult life-years lived as well as the present life expectancy deficit are almost exclusively due to di

139 By 2014, the life expectancy deficit had decreased to 1.2 years for m

140 is and HIV were responsible for 84.9% of the life expectancy deficit in men and 80.8% in women.

141 that of the HIV-negative population (ie, the life expectancy deficit).

142 In the bottom income quartile, life expectancy differed by approximately 4.5 years betw

143 istent with truncated development, shortened life expectancies, elevated mortality rates and higher e

144 Progress in women's life expectancy exceeded that of men, in whom negligible

145 Improvements in female life expectancy exceeded those in male life expectancy i

146 s ratios (ICERs), using discounted costs and life expectancies for all HIV-exposed (infected and unin

147 Life expectancies for US patients were estimated accordi

148 Fourth, geographic differences in life expectancy for individuals in the lowest income qua

149 veloped a multistate life table to calculate life expectancy for individuals who were normal weight,

150 Third, life expectancy for low-income individuals varied substa

151 Life expectancy for low-income individuals was positivel

152 to all MDR patients resulted in the highest life expectancy for our initial cohort averaged across a

153 receptors PD-1 and CTLA-4 and have improved life expectancy for patients across a range of tumor typ

154 bles analyses were used to estimate gains in life expectancy for the exposures.

155 le to survive to older ages than males, with life expectancy for the least frail adult females reachi

156 e causing loss of motor function and reduced life expectancy, for which limited treatment is availabl

157 Life expectancy from age 20 years was an additional 48.1

158 Between 1990 and 2013, life expectancy from birth in England increased by 5.4 y

159 From 1990 to 2013, life expectancy from birth in Mexico increased by 3.4 ye

160 ed US smokers aged 40 years lose >6 years of life expectancy from smoking, possibly outweighing the l

161 cohort, the mean (2.5th, 97.5th percentile) life expectancy from time of initiation of MDR TB treatm

162 ncreased substantially (1219 of 100 000 men, life expectancy gain: 65 days; 1204 of 100 000 women, li

163 ctancy gain: 65 days; 1204 of 100 000 women, life expectancy gain: 71 days).

164 Life expectancy gains and deficits were further disaggre

165 itiating aspirin at ages 40 to 69 years, and life expectancy gains are expected for most men and wome

166 and Serbia have some of the lowest projected life expectancy gains for both men and women.

167 ted mortality account for 79.7% of the total life expectancy gains in men (8.4 adult life-years), and

168 eneral population, averted cancer deaths and life expectancy gains increased substantially (1219 of 1

169 for RT based on age alone, although a short life expectancy generally might preclude RT.

170 Residents with a life expectancy greater than 4 weeks who consented to tr

171 rombosis (DVT) or pulmonary embolism, with a life expectancy greater than 6 months and without contra

172 Conversely, 14.1% of those with life expectancy > 10 years did not report mammography.

173 unknown benefits, whereas 14% with estimated life expectancy > 10 years did not report mammography.

174 We aimed to estimate health-adjusted life expectancy (HALE) among adults living with and with

175 -years (DALYs), life expectancy, and healthy life expectancy (HALE) in Japan and its 47 prefectures.

176 ity-adjusted life-years (DALYs), and healthy life expectancy (HALE) in Mexico and its 32 states, alon

177 Driven by technological progress, human life expectancy has increased greatly since the nineteen

178 Life expectancy has risen among middle-income and high-i

179 Absolute differences in life expectancy, healthy life expectancy, and life expec

180 onal level, treating HCV before LT increased life expectancy if MELD was </=27 but could decrease lif

181 Evaluation of age-specific factors such as life expectancy, impaired functional status, and cogniti

182 6.7 years, the same as the highest worldwide life expectancy in 2012, and a 57% probability that it w

183 emale life expectancy exceeded those in male life expectancy in all provinces except Shanghai, Macao,

184 homeostasis is a biomarker and predictor of life expectancy in Caenorhabditis elegans.

185 The gap between female life expectancy in Denmark vs. Sweden grew to 3.5 y in t

186 tudy the remarkable recent history of female life expectancy in Denmark, a saga of rising, stagnating

187 (HAART) has improved the immune function and life expectancy in HIV-infected patients whose respirato

188 Life expectancy in King County, WA, USA, is in the 95th

189 EVAR does not increase overall life expectancy in patients ineligible for open repair,

190 We studied life expectancy in patients who had received curative tr

191 on and other factors have contributed to the life expectancy in patients with CML approaching that of

192 odel to reflect increased CRC risk and lower life expectancy in patients with cystic fibrosis.

193 odel to reflect increased CRC risk and lower life expectancy in patients with cystic fibrosis.

194 We also examined whether any loss of life expectancy in patients with type 1 diabetes is conf

195 excessive cardiovascular deaths and reduced life expectancy in schizophrenia.

196 Projected female life expectancy in South Korea is followed by those in F

197 resulted in a reduction in life expectancy; life expectancy in Syria would have been 5 years higher

198 ) have not taken into account differences in life expectancy in the general population.

199 m those that contributed most to increase in life expectancy; in particular, they affect mortality at

200 Since the roll-out of ART in 2004, adult life expectancy increased by 15.2 years for men (95% CI

201 Between 2001 and 2014, life expectancy increased by 2.34 years for men and 2.91

202 Between 1981 and 2012, life expectancy increased by 8.2 years for men and 6.0 y

203 Male adult life expectancy increased from 46.9 y (95% CI 45.6, 48.2

204 Second, inequality in life expectancy increased over time.

205 dementia is expected to soar as the average life expectancy increases, but recent estimates suggest

206 l health care is of increasing importance as life expectancy is being prolonged extensively among PLW

207 Hence, the lower Danish life expectancy is caused by these cohorts and is not at

208 The global increase in life expectancy is creating significant medical, social

209 dministered, whether a patient's anticipated life expectancy is extraordinary, and whether a patient'

210 In particular, the black-white gap in life expectancy is greater at higher levels of education

211 d cessation of mammography in patients whose life expectancy is less than 5 years to 10 years, regard

212 in every country except Mexico, where female life expectancy is predicted to increase more than male

213 Life expectancy is projected to increase in all 35 count

214 The relationship between income and life expectancy is well established but remains poorly u

215 ses linked to ART per 1,000 ART initiations, life expectancy (LE, in years) and per-person lifetime H

216 ncy by income group; geographic variation in life expectancy levels and trends by income group; and f

217 a, and Syria have resulted in a reduction in life expectancy; life expectancy in Syria would have bee

218 es are now out of date because of changes in life expectancy, living conditions, and health profiles.

219 cratic), where stress is typically lower and life expectancies longer.

220 ast cancer survivors with an estimated short life expectancy (< 5 years) receive annual surveillance

221 >/=85 y, those with >/=20 teeth had a longer life expectancy (men: +57 d; women: +15 d) and healthy l

222 tancy (men: +57 d; women: +15 d) and healthy life expectancy (men: +92 d; women: +70 d) and a shorter

223 Life expectancy, modeled from ARISTOTLE outcomes, was si

224 th and social services, future mortality and life expectancy need to be forecast.

225 n patients with cystic fibrosis, with median life expectancy now older than 40 years.

226 pproximately 8.6% and 35.1% had an estimated life expectancy of </= 5 and </= 10 years, respectively.

227 rapy on admission was associated with longer life expectancy of 0.78 (standard error [SE]: 0.05), 0.5

228 their overall health is good and they have a life expectancy of 10 years or longer (qualified recomme

229 8.20 x 10(-7)) translating to a reduction in life expectancy of 2.9 years for males and 2.6 years for

230 ordant care), the no EID strategy produced a life expectancy of 21.1 years (in the HIV-infected group

231 bilitating neurodegenerative disease, with a life expectancy of 3-5 years from first symptom.

232 y Group performance status of 2 or less, and life expectancy of 6 months or less.

233 nsionally measurable disease (by CT or MRI); life expectancy of 6 months or more; adequate haematolog

234 surgery per country for 2012 associated with life expectancy of 74-75 years; estimated rates of surge

235 The life expectancy of adult O. volvulus is reduced by appro

236 nts with Stage D heart failure with a median life expectancy of approximately 10 to 15 years.

237 e not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to

238 e not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to

239 e not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to

240 rgan function and laboratory test results, a life expectancy of at least 12 weeks, and having recover

241 Oncology Group performance status of 0 or 1, life expectancy of at least 3 months, and at least one m

242 y Group (ECOG) score of 0-2 and a documented life expectancy of at least 3 months.

243 of HIV disease and treatment to project the life expectancy of HIV-infected persons, based on smokin

244 The life expectancy of HIV-positive individuals receiving an

245 es after maturity, far longer than the short life expectancy of Hydra in the wild.

246 omegaly, and hepatic failure, and an average life expectancy of less than 4 months.

247 reatly increased the quality of life and the life expectancy of many patients with rheumatoid arthrit

248 We assessed how these changes affected the life expectancy of patients with CML and life-years lost

249 d leukemia (CML) treatment, transforming the life expectancy of patients; however the risk for relaps

250 The increased life expectancy of persons infected with human immunodef

251 The life expectancy of the average American with diabetes ha

252 The life expectancy of the wealthiest Americans now exceeds

253 Vast improvements in the life expectancy of these patients were seen over the stu

254 ipt of mammography decreased with decreasing life expectancy ( P < .001), although 56.7% and 65.9% of

255 tions by age group and cause, and forecasted life expectancy pathways for Mexico to converge to bette

256 costs through 12 months were used to project life expectancy, quality-adjusted life expectancy, and l

257 Endpoints were survival, life expectancy, quality-adjusted life-years (QALYs), nu

258 In 2014, life expectancy ranged from 68.4 years (95% UI 66.9-70.1

259 For men, life expectancy ranged from 70.2 to 77.5 years and for w

260 Total life expectancy remained unaffected by overweight and ob

261 ife expectancy; 1 year less of pretransplant life expectancy required an increase of 1.49 years in po

262 ued to smoke lost 6.7 years and 6.3 years of life expectancy, respectively, compared with never smoke

263 se with estimated </= 5-year and </= 10-year life expectancy, respectively, reported mammography in t

264 We compared these strategies according to life expectancy, risks of acquired resistance, and the e

265 lasma cell malignancy leading to significant life-expectancy shortening.

266 tables from age-specific mortality rates and life expectancy stratified by sex, CD4 cell count, and W

267 Long-standing racial differences in US life expectancy suggest that black Americans would be ex

268 en living with HIV, had much shorter overall life expectancies than did their HIV-negative counterpar

269 after acute myocardial infarction had longer life expectancies than patients treated in low-performin

270 spanics in the United States having a longer life expectancy than Caucasians despite having a higher

271 t ventricular ejection fraction, and shorter life expectancy than isolated postcapillary PH.

272 ave disproportionally worse health and lower life expectancy than their non-indigenous counterparts i

273 consider cessation while taking into account life expectancy, the estimated risk for subsequent in-br

274 ow SES to increased disease risk and reduced life expectancy, the underlying biology remains poorly u

275 an increase of 1.49 years in posttransplant life expectancy to compensate.

276 The great improvements in life expectancy translated into great reductions in the

277 Relationship between income and life expectancy; trends in life expectancy by income gro

278 e I) to limited motor neuron loss and normal life expectancy (type IV).

279 forecast national age-specific mortality and life expectancy using an approach that takes into accoun

280 within the last 12 months by 5- and 10-year life expectancy (using the validated Schonberg index), a

281 Discounted life expectancy was 16.69 years for SOC, 16.97 years wit

282 Life expectancy was 9.3 years (5.4-13.1) shorter in part

283 Life expectancy was estimated by using Cox proportional

284 tion c.1903C>T lived longer than the others, life expectancy was greatly diminished (10.8 vs. 4.6 mon

285 In adjusted analyses, lower ( v higher) life expectancy was significantly associated with lower

286 The OS curves crossed, so life expectancy was used: 15.7 months in the ADI-PEG20 g

287 Pretransplant life expectancy was valued more highly than posttranspla

288 The differences in life expectancy were correlated with health behaviors an

289 provider-patient discussions about prognosis/life expectancy were examined for their association with

290 0% probability that by 2030, national female life expectancy will break the 90 year barrier, a level

291 of 45 kg/m gained an additional 6.7 years of life expectancy with bariatric surgery (38.4 years with

292 ncy (men: +92 d; women: +70 d) and a shorter life expectancy with disability (men: -35 d; women: -55

293 ife expectancy, healthy life expectancy, and life expectancy with disability according to the number

294 ression of morbidity: older Japanese adults' life expectancy with disability was compressed by 35 to

295 However, life expectancy with disability will increase more in re

296 on of morbidity, measured as a shortening of life expectancy with disability, an extension of healthy

297 r who report recent discussions of prognosis/life expectancy with their oncologists come to have a be

298 that they never had discussions of prognosis/life expectancy with their oncologists.

299 to 0.70; P = 0.028) discussions of prognosis/life expectancy with their oncologists.

300 eported only recent discussions of prognosis/life expectancy with their oncologists; 68 (38%) reporte

301 d with HCM can achieve normal or near-normal life expectancy without disability, and usually do not r